Myriad Strengthens Commitment To Cancer Research At The ASCO 50th Annual Meeting

SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from 11 clinical studies with its molecular diagnostic tests will be featured at the 2014 American Society of Clinical Oncology annual meeting to be held May 30-June 3, 2014 in Chicago, Ill. Abstracts of the Company's presentations are available at:

The molecular diagnostic tests being highlighted at ASCO address four key areas of focus for Myriad including hereditary cancer, melanoma, companion diagnostics and prostate cancer. There will be presentations on six new key studies on the Myriad myRisk™ Hereditary Cancer test, including two podium presentations; two presentations on the Myriad myPath™ Melanoma test, including the first pivotal clinical validation study; and the presentation of new clinical data on the HRD companion diagnostic in patients with metastatic triple negative breast cancer.

"Myriad is committed to advancing all aspects of cancer care – risk assessment, diagnosis, prognosis and treatment selection – and has a robust portfolio and pipeline of molecular and companion diagnostics," said Mark Capone, president of Myriad Genetics Laboratories. "We believe much more can be done through diagnostics to improve patient care and lower health care costs. Through our strong internal and external research programs, Myriad is leading the discovery, development and commercialization of the next generation of diagnostic tests and services."

The list of key Myriad presentations follows.
Myriad myRisk Hereditary Cancer Testing  
Title:  A study of ovarian cancer patients tested with a 25-gene panel of hereditary cancer genes.
Presenter:  Lucy Langer  
Date:  Monday, June 2, 8:48 a.m. - 9:00 a.m. (Podium Presentation; Location S100a)
Title:  Multigene panel testing in patients suspected to have Lynch syndrome.
Presenter:  Matthew Yurgelun 
Date:  Monday, June 2, 8:00 a.m. - 8:12 a.m. (Podium Presentation; Location S100a)
Title:  Analysis of patients with two hereditary cancers (breast/ovarian or colon/endometrial) who met NCCN genetic testing criteria after their first cancer.
Presenter:  Jennifer Saam
Date:  Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1542)
Title:  Impact of 25-gene panel testing and integrated risk management tool on medical management in hereditary cancer syndrome evaluation.
Presenter:  Lee Schwartzberg
Date:  Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1553)
Title:  The clinical experience: Hereditary cancer testing by a 25-gene panel.
Presenter:  Elias Obeid
Date:  Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1548)
Title:  Evaluation of breast cancer incidence in Lynch syndrome patients by MMR gene.
Presenter:  Jamie Willmott
Date:  Sunday, June 1, 8:00 a.m. - 11:45 a.m. (Poster 1541)
Myriad myPath Melanoma  
Title:  Development and validation of a gene expression signature to distinguish malignant melanoma from benign nevi.
Presenter:  Colleen Rock
Date:  Monday, June 2, 8:00 a.m. - 12:00 p.m.; Discussion 11:30 a.m. – 12:45 p.m. (Highlighted Poster 9021)
Title:  The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists.
Presenter:  Loren Clarke
Date:  Saturday, May 31, 8:00 a.m. - 11:45 a.m. (Poster TPS9111)
HRD (Companion Diagnostic)  
Title:  Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple negative breast cancer (mTNBC): Correlative studies from TBCRC009.
Presenter:  Steven Isakoff
Date:  Tuesday, June 3, 9:45 a.m. - 12:45 p.m. (Podium Presentation; Location E Hall D1)
Title:   TBCRC030: A randomized phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple negative breast cancer (TNBC): Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Presenter:  Erica Mayer
Date:  Monday, June 2, 8:00 a.m. - 11:45 a.m. (Poster TPS1445)
Title:  Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort
Presenter:  Jack Cuzick
Date:  Monday, June 2, 1:15 p.m. - 5:00 p.m. (Poster 5059)

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: .

Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, and Myriad myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments